Nicholas Kian Mollanazar, MD, MBA
he/him/his
Dermatology
Accepting new patients
Sees patients age 18 and up
Penn Dermatology Perelman
Schedule onlineCall 215-662-2737
Penn Medicine Provider

About me

  • Co-Chair, Electronic Medical Record Governance, Department of Dermatology
  • Director, Dermatology Patient Access
  • Applied Informatics Specialist, Dermatology
  • Assistant Professor of Clinical Dermatology

Education and training

  • Medical School: Temple University
  • Residency: Pennsylvania Hospital
  • Residency: Temple University Hospital

What my patients think about me

Average Rating

1844 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

February 2026
kind and knowledgeable
February 2026
very professional
February 2026
he was great!
January 2026
very personable

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Mollanazar is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Anusionwu I, Puerta Durango K, Barrera TM, Ogunleye T, Taylor SC, Mollanazar NK The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients with Atopic Dermatitis: A Retrospective Chart Review , J Drugs Dermatol, 24(10): 2025,1054-55

Ruiz Dasilva D, Soto-González A, Mollanazar NK, Ndubisi S, Issa N, Song JE, Shahriari M, Bunick CG, Lio P, Nguyen HP, Yosipovitch G, Del Rosso J Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series , J Clin Aesthet Dermatol, 18(9): 2025,40-46

Mollanazar N, Doran J, Nguyen T, Pivneva I, Signorovitch J, Sullivan R, Voegel A, Uritsky T, et al Delayed biologic initiation is associated with increased healthcare resource use in patients diagnosed with hidradenitis suppurativa , Journal of the American Academy of Dermatology, 93(3): 2025,AB163

Kwatra SG, Pereira MP, Misery L, Mollanazar NK, Shah P, Wiggins S Prurigo nodularis: disease burden, clinical features and approach to management , Br J Dermatol, 193(4): 2025,642-52

Mollanazar N, Isaman DL, Wiggins S, Sivamani RK, Chih-Ho Hong H, Chovatiya R, Yu T, Zahn J, Petruski-Ivleva N, Bosman K, et al: Real-World Medication Use Prior to Dupilumab Initiation Among Adult Patients With Prurigo Nodularis in the US , Journal of the American Academy of Dermatology, 93(3): 2025,AB285

Anusionwu I, Puerta Durango K, Barrera TM, Ogunleye T, Taylor SC, Mollanazar N The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review , J Drugs Dermatol, 24(8): 2025,8749

Mehta A, Perry N, Encarnacion I, Mollanazar N, Taylor SC Disparities in Alopecia Areata and Vitiligo FDA-Approved Therapies in Medicaid Formularies , J Drugs Dermatol, 24(3): 2025,e17

Ruiz Dasilva D, Desir N, Encarnacion IN, Issa N, Song EJ, Mollanazar NK Achievement of Optimal Treatment Targets with Oral Janus Kinase Inhibition in Elderly Patients with Atopic Dermatitis: A Real-world, Multicenter, Retrospective Study , J Clin Aesthet Dermatol, 18(2): 2025,25-29

Butler DC, Berger T, Elmariah S, Kim B, Chisolm S, Kwatra SG, Mollanazar N, Yosipovitch G Chronic Pruritus: A Review , JAMA, 331(24): 2024,2114 - 24

Obeng-Nyarko CN, Puerta Durango K, Jackson S, Rodriguez O, Mollanazar NK Dupilumab for the treatment of pityriasis lichenoides chronica , JAAD Case Rep, 50: 2024,9-11

View all publications